Lyophilized formulation comprising tat-NR2B9C, histidine and trehalose
US10251935B2 · kind B2 · utility
4Cited by
5References
10Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Jul 14, 2016 |
| Grant date | Apr 9, 2019 |
| Priority date | — |
| Expiry date | Jul 14, 2036 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2300/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides lyophilized formulations of active agents, particularly of TAT-NR2B9c. TAT-NR2B9c has shown promise for treating stroke, aneurysm, subarachnoid hemorrhage and other neurological or neurotraumatic conditions. Such formulations are stable at room temperature thus facilitating maintenance of supplies of such a formulation in ambulances for administration at the scene of illness or accident or in transit to a hospital.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.